While PHQ‐2 ≥ 3 was associated with reports of anemia (53% vs 46%, P = .04), there was no difference in reported depressive symptoms and anemia‐directed therapies including recent transfusions (prior 6 months) (P = .25), erythropoietin injections (P = .3), or iron supplementation (P = .9). This evidence concerns the gene EPO and anemia.